OncoSec Medical is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for the treatment of solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). ONCS’ clinical programs include three phase 2 clinical trials for ImmunoPulse targeting lethal skin cancers. For more information visit the company’s Web site at www.oncosec.com
Let us hear your thoughts below: